Cencora Inc. (COR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cencora Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 311.30 $ — 48% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 14.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | 17.78 | 17.70 – 17.84 | 336,893 | 11.2% | 13 |
| 09/30/2027 | 19.82 | 19.32 – 20.13 | 358,031 | 11.4% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 4.37 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 2.50 | -16.00 | 81,487 | 12.80 | 0.60 | -2,719 | -2,825 |
| 2025: Q1 | 3.68 | 75.90 | 75,454 | 10.30 | 1.00 | 3,351 | 3,222 |
| 2025: Q2 | 3.52 | 45.70 | 80,664 | 8.70 | 0.90 | 109 | -74 |
| 2025: Q3 | -1.75 | -10,475.20 | 83,729 | 5.90 | -0.40 | 3,133 | 2,884 |
| 2025: Q4 | 2.87 | 14.50 | 85,932 | 5.50 | 0.70 | -2,305 | -2,425 |
| 2026: Q1 | 8.40 | 128.30 | 78,356 | 3.80 | 2.10 | 1,339 | 1,173 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 146,850 | 1,683 | 1,428 | 6.32 | 3,179 | 2,129 | 33,590 |
| 2017 | 153,144 | 2,018 | 414 | 1.87 | 1,489 | 2,064 | 35,316 |
| 2018 | 167,940 | 1,651 | 1,658 | 7.53 | 1,411 | 2,933 | 37,670 |
| 2019 | 179,589 | 1,867 | 855 | 4.04 | 2,344 | 2,879 | 39,172 |
| 2020 | 189,894 | 2,025 | -3,400 | -16.60 | 2,207 | -1,019 | 44,275 |
| 2021 | 213,989 | 2,675 | 1,540 | 7.39 | 2,667 | 223 | 57,338 |
| 2022 | 238,587 | 2,752 | 1,699 | 8.04 | 2,703 | -212 | 56,561 |
| 2023 | 262,173 | 2,447 | 1,745 | 8.53 | 3,911 | 522 | 62,559 |
| 2024 | 293,959 | 3,040 | 1,509 | 7.53 | 3,485 | 646 | 67,102 |
| 2025 | 321,333 | 3,648 | 1,554 | 7.96 | 3,875 | 1,508 | 76,590 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Cencora, Inc. beschafft und vertreibt pharmazeutische Produkte in den USA und international.
| Employees | 47,000 |
|---|---|
| Headquarters | Conshohocken, PA |
| Address | 1 West First Avenue, 19428-1800 Conshohocken, United States |
| Phone | 610 727 7000 |
| Website | cencora.com |
| IPO Date | 4. Apr 1995 |
| ISIN | US03073E1055 |
| Stock Split | 2:1 on 06/16/2009 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Robert P. Mauch Ph.D., PharmD | President, CEO & Director | 1967 |
| Elizabeth S. Campbell J.D. | Executive VP & Chief Legal Officer | 1975 |
| Eva C. Boratto | Executive VP & CFO | 1967 |
| Lazarus Krikorian | Senior VP, Chief Accounting Officer & Corporate Controller | 1965 |
| Pawan Singh Verma | Executive VP and Chief Data & Information Officer | 1977 |
| Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.